Agile Therapeutics (NASDAQ:AGRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report released on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a hold rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

Agile Therapeutics Price Performance

Shares of Agile Therapeutics stock opened at $0.37 on Wednesday. Agile Therapeutics has a 52-week low of $0.20 and a 52-week high of $4.06. The company has a 50 day moving average of $0.39 and a 200 day moving average of $1.19. The company has a market capitalization of $2.57 million, a P/E ratio of -0.10 and a beta of 1.25.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter. The company had revenue of $5.72 million for the quarter.

Institutional Trading of Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC increased its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.